Virtu Financial LLC Makes New Investment in Quince Therapeutics, Inc. (NASDAQ:QNCX)

Virtu Financial LLC purchased a new position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 29,204 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 0.07% of Quince Therapeutics as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Geode Capital Management LLC raised its stake in Quince Therapeutics by 24.2% during the 3rd quarter. Geode Capital Management LLC now owns 339,125 shares of the company’s stock valued at $263,000 after purchasing an additional 66,170 shares during the last quarter. Scharf Investments LLC acquired a new position in shares of Quince Therapeutics during the fourth quarter valued at about $170,000. Finally, Anfield Capital Management LLC acquired a new position in shares of Quince Therapeutics during the fourth quarter valued at about $50,000. 30.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

QNCX has been the topic of several research reports. Brookline Capital Management started coverage on Quince Therapeutics in a research note on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target on the stock. Oppenheimer started coverage on Quince Therapeutics in a research report on Monday, March 24th. They set an “outperform” rating and a $10.00 price objective on the stock. Finally, D. Boral Capital reduced their target price on Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $8.00.

Quince Therapeutics Stock Performance

Quince Therapeutics stock opened at $1.33 on Tuesday. The firm has a market capitalization of $58.52 million, a P/E ratio of -1.07 and a beta of 0.71. The stock has a fifty day moving average price of $1.46 and a two-hundred day moving average price of $1.46. Quince Therapeutics, Inc. has a 52-week low of $0.51 and a 52-week high of $2.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53.

Quince Therapeutics (NASDAQ:QNCX) last announced its earnings results on Monday, March 24th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The company had revenue of $0.17 million for the quarter. As a group, analysts anticipate that Quince Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.